In resistant EGFR-mutant NSCLC cell lines, we demonstrated that PPP3CB up-regulation reduces sensitivity to EGFR TKIs by activating the MEK/ERK signaling pathway. The gene discussed is PPP3CB; the disease is non-small cell lung carcinoma.